The Danish pharmaceutical giant Novo Nordisk initiated a revolution in weight management with its groundbreaking therapies Ozempic and Wegovy. However, the company now faces a period of substantial upheaval following
All posts tagged in obesity drugs
7Articles
Danish pharmaceutical giant Novo Nordisk has revised its profit forecasts downwards for the fourth time this year as competition in the slimming and diabetes treatments market continues to grow. The
Novo Nordisk, the Danish pharmaceutical giant best known for developing the weight-loss injection Wegovy, has announced a landmark deal to acquire US-listed biotech Akero Therapeutics for up to $5.2 billion.
The American pharmaceutical giant Pfizer has discontinued the development of its experimental weight-loss pill following safety concerns, marking a significant setback in its pursuit of the lucrative anti-obesity market, estimated
The Swiss pharmaceutical giant Roche has announced a partnership with Danish biotechnology firm Zealand Pharma in a deal valued at up to $5.3 billion. The collaboration aims to develop and
A groundbreaking series A funding round has positioned London-based Verdiva Bio at the forefront of the obesity treatment sector, securing an impressive $411 million investment. This remarkable achievement stands as
Danish pharmaceutical giant Novo Nordisk witnessed a staggering $100 billion erosion in market value following disappointing results from its latest obesity drug trial. The company’s shares experienced their most significant
